Benzinga | Sep 7, 2021 09:30AM EDT

BioDelivery Sciences To Exhibit 3 Scientific Posters Comparing BELBUCA To Oxycodone At PAINWeek 2021 Conference

* Risk Stratification of Respiratory Depression With Buprenorphine Buccal Film Versus Oxycodone: Outcomes From a Phase 1 Placebo-Controlled Trial Authors: Lynn Webster, MD; Jacqueline Cater, PhD; Thomas Smith, MD

* Buprenorphine Buccal Film Versus Oral Oxycodone: Secondary Respiratory, Pharmacokinetic, and Pupillometry Outcomes From a Phase 1 Placebo-Controlled Trial Authors: Lynn Webster, MD; Jacqueline Cater, PhD; Thomas Smith, MD

* Buprenorphine Buccal Film Versus Oral Oxycodone: Effects on Pupillometry and Respiratory Depression in a Phase 1 Placebo-Controlled Trial Authors: Lynn Webster, MD; Jacqueline Cater, PhD; Thomas Smith, MD

"These posters include important scientific data for healthcare professionals to consider concerning the safety profile of buprenorphine buccal film and oxycodone," said Thomas Smith, MD, Chief Medical Officer of BDSI. "We are pleased to share these data with healthcare professionals who treat chronic pain patients at this year's PAINWeek Conference."

Important Safety Information About BELBUCA(r)

BELBUCA(r) (buprenorphine buccal film), CIII is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.